Opus Genetics (IRD) Total Non-Current Liabilities (2010 - 2026)

Opus Genetics (IRD) has 17 years of Total Non-Current Liabilities data on file, last reported at $10.5 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 56.55% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 56.55% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, down 21.12% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $10.5 million, up from $8.9 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for IRD reached as high as $30.2 million in Q3 2025 and fell as low as $2.7 million in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $8.9 million across 5 years, with a median of $5.7 million in 2023.
• Across the five-year window, Total Non-Current Liabilities surged 404.81% in 2025 and tumbled 56.55% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $2.8 million in 2022, then jumped by 45.91% to $4.0 million in 2023, then jumped by 181.18% to $11.3 million in 2024, then fell by 21.12% to $8.9 million in 2025, then advanced by 18.27% to $10.5 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $10.5 million in Q1 2026, $8.9 million in Q4 2025, and $30.2 million in Q3 2025.